title: Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of residual masses sufficient?
abstract: OBJECTIVE
  To determine if post-chemotherapy retroperitoneal lymphadenectomy for residual masses can be limited to resection of the residual masses and a modified template dissection, without loss of therapeutic efficacy.
  
  
  METHODS
  Between 1985 and 1995, 50 patients underwent one of three types of retroperitoneal lymphadenectomy for a residual mass after cisplatin-based chemotherapy for stages II and III testicular non-seminomatous germ cell tumour. The pre-operative imaging, operative record and pathology reports were reviewed to determine the location of the residual masses and whether tumour, defined as teratoma or viable carcinoma, was within the boundaries of the modified template and/or residual masses. The median (range) follow-up was 56 (1-140) months.
  
  
  RESULTS
  Of 39 patients undergoing a bilateral dissection, one (2.6%) with a left testicular cancer had teratoma identified outside the boundaries of the modified template and the residual masses. The nine patients who underwent resection of residual masses and a modified-template dissection were relapse-free at a median follow-up of 55 months. One of two patients undergoing resection of residual mass alone had two recurrences arising from incomplete resection. Four of eight patients undergoing a modified dissection retained ejaculation, compared with seven of 25 (28%) undergoing a non-nerve sparing bilateral dissection.
  
  
  CONCLUSIONS
  This retrospective study suggests that in patients whose tumour markers become normal and have a residual mass after chemotherapy, residual masses can be resected with a modified-template dissection with no significant risk of leaving tumour in the retroperitoneum.
authors.affiliation: Urology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
authors.forename: F
authors.initials: F
authors.lastname: Rabbani
authors.forename: S L
authors.initials: SL
authors.lastname: Goldenberg
authors.forename: M E
authors.initials: ME
authors.lastname: Gleave
authors.forename: R F
authors.initials: RF
authors.lastname: Paterson
authors.forename: N
authors.initials: N
authors.lastname: Murray
authors.forename: L D
authors.initials: LD
authors.lastname: Sullivan
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004542:Ejaculation; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision / Q000379:methods*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D018365:Neoplasm, Residual; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy* / Q000601:surgery; D012189:Retrospective Studies; D013736:Testicular Neoplasms / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin